Tissue Regenix Group PLC’s Buy Rating Reaffirmed at Jefferies Group (TRX)
Tissue Regenix Group PLC (LON:TRX)‘s stock had its “buy” rating reaffirmed by analysts at Jefferies Group in a research report issued to clients and investors on Wednesday. They currently have a GBX 29 ($0.49) price target on the stock. Jefferies Group’s target price would suggest a potential upside of 7.41% from the stock’s previous close.
Shares of Tissue Regenix Group PLC (LON:TRX) traded down 1.82% during mid-day trading on Wednesday, hitting GBX 27.00. 283,159 shares of the company’s stock traded hands. Tissue Regenix Group PLC has a 52 week low of GBX 18.52 and a 52 week high of GBX 30.485. The stock’s 50-day moving average is GBX 0. and its 200-day moving average is GBX 0..
Tissue Regenix Group plc, is a United Kingdom-based holding company. It is a regenerative medical devices company, which uses animal or human tissue to replace damaged or worn out parts of the human body.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.